1-(氯甲氧基甲基)萘 | 88045-68-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 1-(氯甲氧基甲基)萘
• 英文名称: chloromethyl 1-methylnaphthyl ether
• 英文别名: 1-[(Chloromethoxy)methyl]naphthalene；1-(chloromethoxymethyl)naphthalene
• CAS: 88045-68-5
• 化学式: C₁₂H₁₁ClO
• 分子量: 206.672
• InChiKey: WNTLAIKNTSXITD-UHFFFAOYSA-N

物化性质

• 沸点：
  98-100 °C(Press: 0.12 Torr)
• 密度：
  1.186±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(氯甲氧基甲基)萘 在 ammonium cerium (IV) nitrate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 水 、 丙酮 为溶剂， 反应 137.0h， 生成 1-萘甲醇
  参考文献：
  名称：

  1-萘甲基和1-萘甲氧基甲基保护基：苄基和苄氧基甲基类型家族的新成员

  摘要：

  1-苄基甲基（NAP I）和1-萘甲氧基甲基（NAPOM I）保护基被开发为苄基和苄氧基甲基类型家族的新成员。NAP我和NAPOM我可以在常规条件，如NAP下引入我比Br /的NaH /室温（rt），或NAPOM我CL /我-Pr 2将EtN / RT。它们也可以在常规条件下去除，例如通过二氯二氰基苯并醌（DDQ）或硝酸铈铵（CAN）介导的氧化，或通过氢解。这些新的保护基的具体优点是：i）与NAPOM II相比，NAPOM I C1的合成成本更低C1，ii）在NAPOM I存在下通过DDQ介导的氧化选择性除去NAPOM II的可能性，以及iii）即使在硬亲核试剂存在下与强酸的相容性。

  DOI：

  10.1016/j.tetlet.2017.04.046
• 作为产物：
  描述：

  1-萘甲醇 在 磺酰氯 、 sodium hydride 、 sodium iodide 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 生成 1-(氯甲氧基甲基)萘
  参考文献：
  名称：

  Pyrimidinones as reversible metaphase arresting agents

  摘要：

  5-Halo-N(1)-substituted 2(1H)-pyrimidinones have the ability to cause reversible arrest of mitosis during metaphase, Highly active compounds have a heteroatom (O, S or N) in the beta-position of the N(1)-carbon chain which is further substituted by an aryl group. In vitro data have been provided. It is suggested that reversible metaphase inhibitors can be used as synchronizing agents of cell-cycles by applying them in a sequential manner when a phase-specific cytotoxic drug is used in the treatment of diseases caused by uncontrolled rapidly proliferating cells. The active compounds are prepared from 2-pyrimidinones by alkylation reactions. The key reactants are alpha-chloroalkyl ethers, sulfides and amides; methods for their syntheses have been described.

  DOI：

  10.1016/0223-5234(93)90014-6

文献信息

• AGENT FOR INTRODUCING PROTECTING GROUP FOR HYDROXY GROUP AND/OR MERCAPTO GROUP
  申请人：KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION

  公开号：US20170305809A1

  公开（公告）日：2017-10-26

  A novel agent for introducing a protecting group for a hydroxy group and/or a mercapto group that can be introduced and removed under mild conditions is provided. The agent for introducing a protecting group for a hydroxy group and/or mercapto group of a substrate compound having the hydroxy group and/or mercapto group is represented by the following formula (I), wherein A represents a ring structure having 1 to 5 rings in which two carbon atoms of an adjacent benzene ring are included, the ring structure comprises a substituted or unsubstituted five-membered ring or six-membered ring and optionally include a heterocycle; each of R 1 , R 2 , R 3 , and R 4 is independently a hydrogen atom or a linear or branched alkyl group having 1 to 5 carbon atoms; and X is a halogen atom or OSO 2 R 5 (R 5 =an aryl group or an alkyl group).

  提供了一种用于在温和条件下引入和去除保护羟基和/或巯基的新型试剂。用于引入底物化合物的具有羟基和/或巯基的保护基的试剂由以下式(I)表示，其中A代表含有1至5个环的环结构，其中包括相邻苯环的两个碳原子，该环结构包括取代或未取代的五元环或六元环，并且可以包括一个杂环；每个R1、R2、R3和R4独立地是氢原子或具有1至5个碳原子的直链或支链烷基基团；X是卤原子或OSO2R5（R5=芳基或烷基）。
• Substituted pyrimidin-2-ones and the salts thereof
  申请人：Nyegaard & Co. A/S

  公开号：US04539324A1

  公开（公告）日：1985-09-03

  Compounds of the general formula: ##STR1## wherein X represents halogen or trifluoromethyl; R.sup.1 and R.sup.2, independently represent hydrogen or lower alkyl; R.sup.3, R.sup.4 and R.sup.5, which may be the same or different, each represent hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower alkenoyl, C.sub.7-16 aralkyl or C.sub.6-10 aryl or a 5-9 membered unsaturated or aromatic heterocyclic ring; one or both of R.sup.4 and R.sup.5 may also represent aroyl groups; Z represents an oxygen atom or a sulfur atom or oxide thereof or a group NR.sup.6 (wherein R.sup.6 is as defined for R hereinafter or represents the group COR.sup.7 in which R.sup.7 represents hydrogen or optionally substituted aryl, heterocyclic, aralkyl, lower alkyl or lower alkoxy group; and R represents a C.sub.6-10 carbocyclic aromatic group or a heterocyclic group containing a 5-9 membered unsaturated or aromatic heterocyclic ring which ring contains one or more heteroatoms selected from O, N and S and optionally carries a fused ring which carbocyclic or heterocyclic group may carry one or more C.sub.1-4 alkyl or phenyl groups said groups being optionally substituted; and where acid or basic groups are present, the salts thereof are useful in combating abnormal cell proliferation. The compounds of the invention are prepared by inter alia alkylation, ring closure and oxidation.

  通式为：##STR1##其中X代表卤素或三氟甲基；R.sup.1和R.sup.2分别代表氢或较低的烷基；R.sup.3、R.sup.4和R.sup.5可以相同或不同，分别代表氢、较低的烷基、较低的烯基、较低的炔基、较低的酰基、较低的烯酰基、C.sub.7-16芳基烷基或C.sub.6-10芳基或5-9成员不饱和或芳香杂环环；R.sup.4和R.sup.5中的一个或两个还可以表示芳酰基；Z代表氧原子或硫原子或其氧化物或基团NR.sup.6（其中R.sup.6如下定义或表示基团COR.sup.7，其中R.sup.7代表氢或可选择取代的芳香基、杂环基、芳基烷基、较低的烷基或较低的烷氧基；R代表C.sub.6-10的碳环芳基或含有5-9成员不饱和或芳香杂环环的杂环基，该环含有O、N和S中选择的一个或多个杂原子，并且可以携带一个或多个C.sub.1-4烷基或苯基，所述基团可以是可选择的取代基；当存在酸性或碱性基团时，其盐在对抗异常细胞增殖方面是有用的。该发明的化合物通过烷基化、环闭合和氧化等方法制备。
• Development of novel HEPT analogs featuring significantly improved anti-resistance potency against HIV-1 through chemical space exploration of the tolerant region I
  作者：Ruo-Lan Zhou、Christophe Pannecouque、Erik De Clercq、Shuai Wang、Fen-Er Chen

  DOI：10.1016/j.bioorg.2023.106783

  日期：2023.11

  interface. Encouraging improvements in anti-resistance efficacy were observed in some of these analogs, with the most promising compound 7 g being 3 to 26 − fold more potent than 3 against five mutant strains (E138K, Y181C, L100I, K103N, and Y188L). This analog surpassed the activity and selectivity of compound 3 by approximately 2-fold (EC50 = 0.007468 μM, SI = 4260). Furthermore, it was found to demonstrate

  我们最近对开发用于 HIV 治疗的 1-[(2-羟基乙氧基)甲基]-6-(苯硫基)胸腺嘧啶 (HEPT) 类似物产生了极大的兴趣，确定了一种有效的非核苷逆转录酶抑制剂 (NNRTI) 3 (EC 50 = 0.01681 μM  ) ，但其治疗效果因其较差的抗耐药性而受到限制。这促使我们寻找具有广谱活性的潜在 HEPT 类似物，通过探索溶剂-蛋白质界面的化学空间，产生了一系列新型 HEPT 类似物。在其中一些类似物中观察到抗耐药性功效的令人鼓舞的改进，其中最有前途的化合物7 g对抗五种突变菌株（E138K、Y181C、L100I、K103N 和 Y188L）的 效力比3强3 至 26 倍 。该类似物的活性和选择性超过化合物3约 2 倍（EC 50  = 0.007468 μM，SI = 4260）。此外，还发现其在体外对 CYP 和 hERG 的抑制作用很弱，并且在体内没有急性毒性。本研究
• Pyrimidinone derivatives
  申请人：NYCOMED AS

  公开号：EP0160573A2

  公开（公告）日：1985-11-06

  Bisulphite adducts of compounds of formula (wherein R represents a group R2-CH-X-(CR4R5)nR3; R' represents a halogen atom or a trifluoromethyl group; R2 represents a hydrogen atom or a C1-4 alkyl, C1-4 alkanoyl or phenyl group; X represents an oxygen or a sulphur atom or a group , where R6 represents a formyl, C1-4 alkanoyl or C1-4 alkoxycarbonyl group; R3 represents a C6-10 carbocyclic aromatic group or a heterocyclic group containing a 5- or 6- membered unsaturated heterocyclic ring which ring contains one or more heteroatoms selected from 0, N and S and optionally carries a fused carbocyclic ring, which carbocyclic or heterocyclic group may carry one or more substituents selected from halogen atoms, C1-4 alkyl, C1-4 alkanoyl, C1-4 alkoxy, C1-4 alkoxycarbonyl, C1-4 alkylthio, hydroxyl, nitro, cyano and formyl groups, -NR7R8 groups (where R is a hydrogen atom or a C1-4 alkyl group, and RB is a hydrogen atom or a C1-4 alkyl, C1-4 alkanoyl or aroyl group) and C1-4 alkyl groups substituted by one or more hydroxy or -NR7R8 groups and halogen atoms; n is an integer having the value 0 or 1; and R4 and R5, which may be the same or different, each is a hydrogen atom or a C1-6 alkyl group) and salts of such adducts have metaphase arrest abilities and desirably good water solubilities and may be useful in combatting abnormal cell proliferation.

  式化合物的亚硫酸氢盐加合物 (其中 R 代表基团 R2-CH-X-(CR4R5)nR3； R' 代表卤素原子或三氟甲基； R2 代表氢原子或 C1-4 烷基、C1-4 烷酰基或苯基； X 代表氧原子、硫原子或基团。 其中 R6 代表甲酰基、C1-4 烷酰基或 C1-4 烷氧羰基； R3 代表 C6-10 碳环芳香基团或含有 5 或 6 成员不饱和杂环的杂环基团，该环含有一个或多个选自 0、N 和 S 的杂原子，并可选择带有一个融合碳环，该碳环或杂环基团可带有一个或多个选自卤素原子的取代基、C1-4烷基、C1-4烷酰基、C1-4烷氧基、C1-4烷氧羰基、C1-4烷硫基、羟基、硝基、氰基和甲酰基、-NR7R8基团（其中R为氢原子或C1-4烷基，RB为氢原子或C1-4烷基、C1-4烷酰基或甲酰基）以及被一个或多个羟基或-NR7R8基团和卤素原子取代的C1-4烷基； n 是数值为 0 或 1 的整数；以及 R4和R5，它们可以相同或不同，各自为氢原子或C1-6烷基）和这类加合物的盐具有移相抑制能力和理想的良好水溶性，可用于抑制异常细胞增殖。
• Quaternary salts of 2-[(hydroxyimino)methyl]imidazole. 3. Synthesis and evaluation of (alkenyloxy)-, (alkynyloxy)-, and (aralykyloxy)methyl quaternarized 2-[(hydroxyimino)methyl]-1-alkylimidazolium halides as reactivators and therapy for soman intoxication
  作者：Clifford D. Bedford、Ralph N. Harris、Robert A. Howd、Dane A. Goff、Gary A. Koolpe、M. Petesch、Irwin Koplovitz、Walter E. Sultan、H. A. Musallam

  DOI：10.1021/jm00122a035

  日期：1989.2

  A series of structurally related monosubstituted 1-[(alkenyloxy)methyl]-, 1-[(alkynyloxy)methyl]-, and 1-[(aralkyloxy)methyl]-2-[(hydroxyimino)methyl]-3-methyli midazolium halides were prepared and evaluated. All new compounds were characterized with respect to (hydroxyimino)methyl acid dissociation constant, nucleophilicity, and octanol-buffer partition coefficient. The alkynyloxy-substituted compounds were also evaluated in vitro with respect to reversible inhibition of human erythrocyte (RBC) acetylcholinesterase (AChE) and kinetics of reactivation of human AChE inhibited by ethyl p-nitrophenyl methylphosphonate (EPMP). In vivo evaluation in mice revealed that coadministration of alkynyloxy-substituted imidazolium compounds with atropine sulfate provided significant protection against a 2 x LD50 challenge of GD. For the alkynyloxy-substituted imidazolium drugs there is a direct relationship between in vitro and in vivo activity: the most potent in vivo compounds against GD proved to be potent in vitro reactivators against EPMP-inhibited human AChE. These results differ from the observations made on the sterically hindered imidazolium compounds (see previous article) and suggest that several antidotal mechanisms of protective action may be applicable for the imidazolium aldoxime family of therapeutics. The ability of the alkynyloxy substituents to provide life-saving protection against GD intoxication was not transferable to the pyridinium or triazolium heteroaromatic ring systems.